Differences in the predominance of lysosomal and autophagic pathologies between infants and adults with Pompe disease: Implications for therapy

Molecular Genetics and Metabolism

Volumn 101, Issue 4, 2010, Pages 324-331

  Raben, Nina ^a   Ralston, Evelyn ^a   Chien, Yin Hsiu ^b   Baum, Rebecca ^a   Schreiner, Cynthia ^a   Hwu, Wuh Liang ^b   Zaal, Kristien J M ^a   Plotz, Paul H ^a  

^a NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES   (United States)

^b NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

Autophagy; Glycogen storage disease; Lysosomal storage; Myopathy

Indexed keywords

ALPHA GLUCOSIDASE; GLYCOGEN;

ARTICLE; AUTOPHAGY; CARDIOMYOPATHY; CLINICAL ARTICLE; CONFOCAL MICROSCOPY; ENZYME DEFICIENCY; ENZYME REPLACEMENT; GLYCOGEN STORAGE DISEASE TYPE 2; HUMAN; INFANT; LYSOSOME; LYSOSOME STORAGE DISEASE; MUSCLE BIOPSY; MYOPATHY; NEWBORN; PRIORITY JOURNAL; SKELETAL MUSCLE;

ADULT; ALPHA-GLUCOSIDASES; AUTOPHAGY; CHILD; CHILD, PRESCHOOL; ENZYME REPLACEMENT THERAPY; GLYCOGEN STORAGE DISEASE TYPE II; HUMANS; INFANT; INFANT, NEWBORN; LYSOSOMES; MUSCLE FIBERS, SKELETAL;

EID: 78649333177     PISSN: 10967192     EISSN: 10967206     Source Type: Journal    
DOI: 10.1016/j.ymgme.2010.08.001     Document Type: Article

References (38)

1. Klionsky D.J. Autophagy revisited: a conversation with Christian de Duve. Autophagy 2008, 4:740-743.
2. Hirschhorn R., Reuser A.J. Glycogen storage disease type II: acid alpha-glucosidase (acid maltase) deficiency. The Metabolic and Molecular Basis of Inherited Disease 2001, 3389-3420. McGraw-Hill, New York, NY. C. Scriver, A. Beaudet, W. Sly, D. Valle (Eds.).
3. Engel A.G., Hirschhorn R., Huie M.L. Acid Maltase Deficiency. Myology 2003, 1559-1586. McGraw-Hill, New York, NY. A.G. Engel, C. Franzini-Armstrong (Eds.).
4. Kishnani P.S., Hwu W.L., Mandel H., Nicolino M., Yong F., Corzo D. A retrospective, multinational, multicenter study on the natural history of infantile-onset Pompe disease. J. Pediatr. 2006, 148:671-676.
5. Winkel L.P., Hagemans M.L., Van Doorn P.A., Loonen M.C., Hop W.J., Reuser A.J., Van der Ploeg A.T. The natural course of non-classic Pompe's disease; a review of 225 published cases. J. Neurol. 2005, 252:875-884.
6. van den Hout H.M., Hop W., van Diggelen O.P., Smeitink J.A., Smit G.P., Poll-The B.T., Bakker H.D., Loonen M.C., de Klerk J.B., Reuser A.J., Van der Ploeg A.T. The natural course of infantile Pompe's disease: 20 original cases compared with 133 cases from the literature. Pediatrics 2003, 112:332-340.
7. Schoser B., Hill V., Raben N. Therapeutic approaches in glycogen storage disease type II/Pompe disease. Neurotherapeutics 2008, 5:569-578.
8. Griffin J.L. Infantile acid maltase deficiency. I. Muscle fiber destruction after lysosomal rupture. Virchows Arch. B Cell Pathol. Incl. Mol. Pathol. 1984, 45:23-36.
9. Thurberg B.L., Lynch M.C., Vaccaro C., Afonso K., Tsai A.C., Bossen E., Kishnani P.S., O'Callaghan M. Characterization of pre- and post-treatment pathology after enzyme replacement therapy for pompe disease. Lab. Invest. 2006, 86:1208-1220.
10. Fukuda T., Ewan L., Bauer M., Mattaliano R.J., Zaal K., Ralston E., Plotz P.H., Raben N. Dysfunction of endocytic and autophagic pathways in a lysosomal storage disease. Ann. Neurol. 2006, 59:700-708.
11. He C., Klionsky D.J. Regulation mechanisms and signaling pathways of autophagy. Annu. Rev. Genet. 2009, 43:67-93.
12. Mizushima N., Levine B., Cuervo A.M., Klionsky D.J. Autophagy fights disease through cellular self-digestion. Nature 2008, 451:1069-1075.
13. Komatsu M., Ueno T., Waguri S., Uchiyama Y., Kominami E., Tanaka K. Constitutive autophagy: vital role in clearance of unfavorable proteins in neurons. Cell Death Differ. 2007, 14:887-894.
14. Levine B., Kroemer G. Autophagy in the pathogenesis of disease. Cell 2008, 132:27-42.
15. Raben N., Shea L., Hill V., Plotz P. Monitoring autophagy in lysosomal storage disorders. Methods Enzymol. 2009, 453:417-449.
16. Ballabio A., Gieselmann V. Lysosomal disorders: from storage to cellular damage. Biochim. Biophys. Acta 2009, 1793:684-696.
17. Raben N., Takikita S., Pittis M.G., Bembi B., Marie S.K.N., Roberts A., Page L., Kishnani P.S., Schoser B.G.H., Chien Y.H., Ralston E., Nagaraju K., Plotz P.H. Deconstructing Pompe disease by analyzing single muscle fibers. Autophagy 2007, 3:546-552.
18. Chien Y.H., Lee N.C., Thurberg B.L., Chiang S.C., Zhang X.K., Keutzer J., Huang A.C., Wu M.H., Huang P.H., Tsai F.J., Chen Y.T., Hwu W.L. Pompe disease in infants: improving the prognosis by newborn screening and early treatment. Pediatrics 2009, 124:e1116-e1125.
19. Wan L., Lee C.C., Hsu C.M., Hwu W.L., Yang C.C., Tsai C.H., Tsai F.J. Identification of eight novel mutations of the acid alpha-glucosidase gene causing the infantile or juvenile form of glycogen storage disease type II. J. Neurol. 2008, 255:831-838.
20. Ralston E., Swaim B., Czapiga M., Hwu W.L., Chien Y.H., Pittis M.G., Bembi B., Schwartz O., Plotz P., Raben N. Detection and imaging of non-contractile inclusions and sarcomeric anomalies in skeletal muscle by second harmonic generation combined with two-photon excited fluorescence. J. Struct. Biol. 2008, 162:500-508.
21. Kabeya Y., Mizushima N., Ueno T., Yamamoto A., Kirisako T., Noda T., Kominami E., Ohsumi Y., Yoshimori T. LC3, a mammalian homologue of yeast Apg8p, is localized in autophagosome membranes after processing. EMBO J. 2000, 19:5720-5728.
22. Kabeya Y., Mizushima N., Yamamoto A., Oshitani-Okamoto S., Ohsumi Y., Yoshimori T. LC3, GABARAP and GATE16 localize to autophagosomal membrane depending on form-II formation. J. Cell Sci. 2004, 117:2805-2812.
23. Raben N., Fukuda T., Gilbert A.L., de Jong D., Thurberg B.L., Mattaliano R.J., Meikle P., Hopwood J.J., Nagashima K., Nagaraju K., Plotz P.H. Replacing acid alpha-glucosidase in Pompe disease: recombinant and transgenic enzymes are equipotent, but neither completely clears glycogen from type II muscle fibers. Mol. Ther. 2005, 11:48-56.
24. Fukuda T., Ahearn M., Roberts A., Mattaliano R.J., Zaal K., Ralston E., Plotz P.H., Raben N. Autophagy and mistargeting of therapeutic enzyme in skeletal muscle in pompe disease. Mol. Ther. 2006, 14:831-839.
25. Kishnani P.S., Corzo D., Nicolino M., Byrne B., Mandel H., Hwu W.L., Leslie N., Levine J., Spencer C., McDonald M., Li J., Dumontier J., Halberthal M., Chien Y.H., Hopkin R., Vijayaraghavan S., Gruskin D., Bartholomew D., Van der P.A., Clancy J.P., Parini R., Morin G., Beck M., De la Gastine G.S., Jokic M., Thurberg B., Richards S., Bali D., Davison M., Worden M.A., Chen Y.T., Wraith J.E. Recombinant human acid [alpha]-glucosidase: major clinical benefits in infantile-onset Pompe disease. Neurology 2007, 68:99-109.
26. Nicolino M., Byrne B., Wraith J.E., Leslie N., Mandel H., Freyer D.R., Arnold G.L., Pivnick E.K., Ottinger C.J., Robinson P.H., Loo J.C., Smitka M., Jardine P., Tato L., Chabrol B., McCandless S., Kimura S., Mehta L., Bali D., Skrinar A., Morgan C., Rangachari L., Corzo D., Kishnani P.S. Clinical outcomes after long-term treatment with alglucosidase alfa in infants and children with advanced Pompe disease. Genet. Med. 2009, 11:210-219.
27. Strothotte S., Strigl-Pill N., Grunert B., Kornblum C., Eger K., Wessig C., Deschauer M., Breunig F., Glocker F.X., Vielhaber S., Brejova A., Hilz M., Reiners K., Muller-Felber W., Mengel E., Spranger M., Schoser B. Enzyme replacement therapy with alglucosidase alfa in 44 patients with late-onset glycogen storage disease type 2: 12-month results of an observational clinical trial. J. Neurol. 2009.
28. Winkel L.P., Van den Hout J.M., Kamphoven J.H., Disseldorp J.A., Remmerswaal M., Arts W.F., Loonen M.C., Vulto A.G., Van Doorn P.A., de Jong G., Hop W., Smit G.P., Shapira S.K., Boer M.A., van Diggelen O.P., Reuser A.J., Van der Ploeg A.T. Enzyme replacement therapy in late-onset Pompe's disease: a three-year follow-up. Ann. Neurol. 2004, 55:495-502.
29. Rossi M., Parenti G., Della C.R., Romano A., Mansi G., Agovino T., Rosapepe F., Vosa C., Del Giudice E., Andria G. Long-term enzyme replacement therapy for pompe disease with recombinant human alpha-glucosidase derived from Chinese hamster ovary cells. J. Child Neurol. 2007, 22:565-573.
30. Van der Ploeg A.T., Clemens P.R., Corzo D., Escolar D.M., Florence J., Groeneveld G.J., Herson S., Kishnani P.S., Laforet P., Lake S.L., Lange D.J., Leshner R.T., Mayhew J.E., Morgan C., Nozaki K., Park D.J., Pestronk A., Rosenbloom B., Skrinar A., van Capelle C.I., van der Beek N.A., Wasserstein M., Zivkovic S.A. A randomized study of alglucosidase alfa in late-onset Pompe's disease. N Engl J. Med. 2010, 362:1396-1406.
31. Raben N., Danon M., Gilbert A.L., Dwivedi S., Collins B., Thurberg B.L., Mattaliano R.J., Nagaraju K., Plotz P.H. Enzyme replacement therapy in the mouse model of Pompe disease. Mol. Genet. Metab. 2003, 80:159-169.
32. Amalfitano A., Bengur A.R., Morse R.P., Majure J.M., Case L.E., Veerling D.L., Mackey J., Kishnani P., Smith W., McVie-Wylie A., Sullivan J.A., Hoganson G.E., Phillips J.A., Schaefer G.B., Charrow J., Ware R.E., Bossen E.H., Chen Y.T. Recombinant human acid alpha-glucosidase enzyme therapy for infantile glycogen storage disease type II: results of a phase I/II clinical trial. Genet. Med. 2001, 3:132-138.
33. Kishnani P.S., Goldenberg P.C., DeArmey S.L., Heller J., Benjamin D., Young S., Bali D., Smith S.A., Li J.S., Mandel H., Koeberl D., Rosenberg A., Chen Y.T. Cross-reactive immunologic material status affects treatment outcomes in Pompe disease infants. Mol. Genet. Metab. 2010, 99:26-33.
34. Kishnani P.S., Corzo D., Leslie N.D., Gruskin D., Van der P.A., Clancy J.P., Parini R., Morin G., Beck M., Bauer M.S., Jokic M., Tsai C.E., Tsai B.W., Morgan C., O'Meara T., Richards S., Tsao E.C., Mandel H. Early treatment with alglucosidase alpha prolongs long-term survival of infants with Pompe disease. Pediatr. Res. 2009, 66:329-335.
35. Kishnani P.S., Nicolino M., Voit T., Rogers R.C., Tsai A.C., Waterson J., Herman G.E., Amalfitano A., Thurberg B.L., Richards S., Davison M., Corzo D., Chen Y.T. Chinese hamster ovary cell-derived recombinant human acid alpha-glucosidase in infantile-onset Pompe disease. J. Pediatr. 2006, 149:89-97.
36. Shieh J.J., Lin C.Y. Frequent mutation in Chinese patients with infantile type of GSD II in Taiwan: evidence for a founder effect. Hum. Mutat. 1998, 11:306-312.
37. Chien Y.H., Chiang S.C., Zhang X.K., Keutzer J., Lee N.C., Huang A.C., Chen C.A., Wu M.H., Huang P.H., Tsai F.J., Chen Y.T., Hwu W.L. Early detection of Pompe disease by newborn screening is feasible: results from the Taiwan screening program. Pediatrics 2008, 122:e39-e45.
38. Griffin J.L. Infantile acid maltase deficiency. I. Muscle fiber destruction after lysosomal rupture. Virchows Arch. B Cell Pathol. Incl. Mol. Pathol. 1984, 45:23-36.